Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemia

References

• Alibhai SM, Leach M, Minden MD, et al. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer. 2009;115(13):2903–2911.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485.
   PubMed Web of Science ®Google Scholar
• Burnett AK. Treatment of acute myeloid leukemia: are we making progress?. Hematol Am Soc Hematol Educ Program. 2012;2012:1–6.
   PubMed Web of Science ®Google Scholar
• Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11(3):275–286.
   PubMedGoogle Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the swedish acute leukemia registry. Blood. 2009;113(18):4179–4187.
   PubMed Web of Science ®Google Scholar
• Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One. 2010;5(4):e10186.
   PubMed Web of Science ®Google Scholar
• Hotinski AK, Lewis ID, Ross DM. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. Expert Opin Pharmacother. 2015;16(9):1395–1402.
   PubMed Web of Science ®Google Scholar
• Galettis P, Boutagy J, Ma DD. Daunorubicin pharmacokinetics and the correlation with p-glycoprotein and response in patients with acute leukaemia. Br J Cancer. 1994;70(2):324–329.
   PubMed Web of Science ®Google Scholar
• Tomita K, Tsuzuki Y, Shibamori K, et al. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1. J Med Chem. 2002;45(25):5564–5575.
   PubMed Web of Science ®Google Scholar
• Gatto B, Capranico G, Palumbo M. Drugs acting on DNA topoisomerases: recent advances and future perspectives. Curr Pharm Des. 1999;5(3):195–215.
   PubMed Web of Science ®Google Scholar
• Ferlin MG, Gatto B, Chiarelotto G, et al. Pyrrolo-quinoline derivatives as potential antineoplastic drugs. Bioorg Med Chem. 2000;8(6):1415–1422.
   PubMed Web of Science ®Google Scholar
• Sissi C, Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anticancer Agents. 2003;3(6):439–450.
   PubMedGoogle Scholar
• Yamashita Y, Ashizawa T, Morimoto M, et al. Antitumor quinolones with mammalian topoisomerase ii mediated DNA cleavage activity. Cancer Res. 1992;52(10):2818–2822.
   PubMed Web of Science ®Google Scholar
• Terada T, Fujimoto K, Nomura M, et al. Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents. Chem Pharm Bull (Tokyo). 1992;40(10):2720–2727.
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Tomita K, Shibamori K, et al. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem. 2004;47(8):2097–2109.
   PubMed Web of Science ®Google Scholar
• Noble CG, Barnard FM, Maxwell A. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex. Antimicrob Agents Chemother. 2003;47(3):854–862.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011;25(12):1808–1814.
   PubMed Web of Science ®Google Scholar
• Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009;64(1):53–65.
   PubMed Web of Science ®Google Scholar
• Walsby EJ, Coles SJ, Knapper S, et al. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 2011;96(3):393–399.
   PubMed Web of Science ®Google Scholar
• Scatena CD, Kumer JL, Arbitrario JP, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010;66(5):881–888.
   PubMed Web of Science ®Google Scholar
• Gammella E, Maccarinelli F, Buratti P, et al. The role of iron in anthracycline cardiotoxicity. Front Pharmacol. 2014;5:25.
   PubMed Web of Science ®Google Scholar
• Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005;68(2):261–271.
   PubMed Web of Science ®Google Scholar
• Jaenke RS, Deprez-DeCampeneere D, Trouet A. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res. 1980;40(10):3530–3536.
   PubMed Web of Science ®Google Scholar
• Mjos KD, Cawthray JF, Jamieson G, et al. Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin. Dalton Trans. 2015;44(5):2348–2358.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Roboz GJ, Cripe LD, et al. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015;100(2):231–237.
   PubMed Web of Science ®Google Scholar
• Stuart RK, Cripe LD, Maris MB, et al. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015;168(6):796–805.
   PubMed Web of Science ®Google Scholar
• Dennis M, Russell N, Hills RK, et al. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015;125(19):2923–2932.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025–1036.
   PubMed Web of Science ®Google Scholar
• Daver NK, Hagop M, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) and high risk myelodysplasic syndrome (MDS). Blood. 2015;126(23):461.
   Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Hills RK, Burnett AK. Applicability of a “pick a winner” trial design to acute myeloid leukemia. Blood. 2011;118(9):2389–2394.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Ravandi F, Ritchie EK, et al. Baseline predictors of mortality in patients with relapsed or refractory acute myeloid leukemia treated with vosaroxin plus cytarabine or placebo plus cytarabine in the phase 3 valor study. Blood. 2015;126(23):2560–2560.
   Google Scholar
• Burnett AK, Hills RK, Hunter A, et al. The addition of arsenic trioxide to low-dose ARA-C in older patients with AML does not improve outcome. Leukemia. 2011;25(7):1122–1127.
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma. 2012;53(1):110–117.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28(4):549–555.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122(8):1384–1394.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27(1):75–81.
   PubMed Web of Science ®Google Scholar
• Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272–279.
   PubMed Web of Science ®Google Scholar
• Kahn SB, Begg CB, Mazza JJ, et al. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1984;2(8):865–870.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. P Natl Acad Sci USA. 2010;107(16):7473–7478.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–569.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and flt-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–4662.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Huang X, Kantarjian H, et al. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010;51(1):73–78.
   PubMed Web of Science ®Google Scholar
• Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011;17(12):1796–1803.
   PubMed Web of Science ®Google Scholar
• Kurosawa S, Yamaguchi T, Miyawaki S, et al. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood. 2011;117(7):2113–2120.
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969–1978.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–1248.
   PubMed Web of Science ®Google Scholar